Benefit–Risk Assessment of Diacerein in the Treatment of Osteoarthritis

Drug Safety

Volumn 38, Issue 3, 2015, Pages 245-252

  Panova, Elena ^a   Jones, Graeme ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAQUINONE DERIVATIVE; ANTIINFLAMMATORY AGENT; DIACEREIN;

CHEMICALLY INDUCED; DIARRHEA; HUMAN; OSTEOARTHRITIS; RADIOGRAPHY; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTHRAQUINONES; ANTI-INFLAMMATORY AGENTS; DIARRHEA; HUMANS; OSTEOARTHRITIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84939940047     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0266-z     Document Type: Review

References (12)

1. Jones G. Sources of pain in osteoarthritis: implications for therapy. Int J Clin Rheumatol. 2013;8:335–46.
2. Fidelix TS, Macedo CR, Maxwell LJ, Fernandes Moça Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014;2:CD005117.
3. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III. Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010;18:476–99.
4. Louthrenoo W, Nilganuwong S, Aksaranugraha S, Asavatanabodee P, Saengnipanthkul S, Thai Study Group. The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled study. Osteoarthritis Cartilage. 2007;15(6):605–14.
5. Pavelka K, Trc T, Karpas K, Vítek P, Sedlácková M, Vlasáková V, Böhmová J, Rovenský J. The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled study with primary end points at two months after the end of a three-month treatment period. Arthritis Rheum. 2007;56(12):4055–64.
6. Kirkham B. Interleukin-1, immune activation pathways, and different mechanisms in osteoarthritis and rheumatoid arthritis. Ann Rheum Dis. 1991;50:395–400.
7. Stannus O, Jones G, Cicuttini F, et al. Circulating levels of IL-6 and TNF-α are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. Osteoarthritis Cartilage. 2010;18:1441–8.
8. Pelletier JP, Yaron M, Haraoui B, et al. Efficacy and safety of diacerein in osteoarthritis of knee: a double-blind, placebo controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000;43(10):2339–48.
9. Dougados M, Nguyen M, Berdah L, et al. Evaluation of structure modifying effect of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial evaluation of the chondromodulating effect of diacerein in osteoarthritis of the hip. Arthritis Rheum. 2001;44(11):2539–47.
10. Lane NE, Brandt K, Hawker G, et al. OARSI–FDA initiative: defining the disease state of osteoarthritis. Osteoarthritis Cartilage. 2011;19:478–82.
11. Spencer CM, Wilde MI. Diacerein. Drugs. 1997;53(1):98–106.
12. Pham T, Le Henanff A, Ravaud P, Dieppe P, Paolozzi L, Dougados M. Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis. Ann Rheum Dis. 2004;63(12):1611–7.